

Accepted Manuscript

Phase I study of the combination of bendamustine, rituximab, and pixantrone in patients with relapsed/refractory B cell non-Hodgkin's Lymphoma

Benjamin Heyman, David Rizzieri, David J. Adams, Carlos deCastro, Louis Diehl, Zhiguo Li, Joseph Moore, Anne Beaven

PII: S2152-2650(18)30329-X

DOI: [10.1016/j.clml.2018.07.285](https://doi.org/10.1016/j.clml.2018.07.285)

Reference: CLML 1173

To appear in: *Clinical Lymphoma, Myeloma and Leukemia*


Received Date: 2 April 2018

Revised Date: 20 June 2018

Accepted Date: 9 July 2018

Please cite this article as: Heyman B, Rizzieri D, Adams DJ, Carlos deCastro Diehl L, Li Z, Moore J, Beaven A, Phase I study of the combination of bendamustine, rituximab, and pixantrone in patients with relapsed/refractory B cell non-Hodgkin's lymphoma, *Clinical Lymphoma, Myeloma and Leukemia* (2018), doi: 10.1016/j.clml.2018.07.285.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Title: Phase I study of the combination of bendamustine, rituximab, and pixantrone in patients with relapsed/refractory B cell non-Hodgkin's lymphoma.

Short Title: Phase I study of BuRP for patients with R/R aNHL.

Authors: Benjamin Heyman¹, David Rizzieri¹, David J. Adams², Carlos deCastro¹, Louis Diehl¹, Zhiguo Li³, Joseph Moore¹, and Anne Beaven¹

Author Affiliations:

¹Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University, Durham, North Carolina, USA.

²Department of Medicine, Duke University, Durham, North Carolina, USA.

³Department of Biostatistics & Bioinformatics, School of Medicine, Duke University, Durham, North Carolina, USA.

Address Correspondence: Dr. Anne Beaven, Division of Hematology/Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina, 170 Manning Drive, CB# 7305, Chapel Hill, NC 27599-7305. Phone: 984-974-8436; Fax: 919-966-6735; E-mail: beaven@med.unc.edu.

Download English Version:

<https://daneshyari.com/en/article/10211920>

Download Persian Version:

<https://daneshyari.com/article/10211920>

[Daneshyari.com](https://daneshyari.com)